Evidence map›Paper›PMID 41869996›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2026

Validation of International Classification of Diseases Code-Based Case Definitions of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis From Administrative Health Data.

Manar Elsayed, Zoe Hsu, Finlay A McAlister, William D Leslie, Lisa M Lix, Sasha Bernatsky, Suzanne N Morin, Michelle M Graham, Aurore Fifi-Mah, Shahin Jamal and 2 more

Abstract readValidation Study
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Manar ElsayedUniversity of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0009-0006-6959-4275
Zoe HsuProvincial Research Data Services, Alberta Health Services, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0003-4441-4216
Finlay A McAlisterUniversity of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0001-7435-3341
William D LeslieUniversity of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0002-1056-1691
Lisa M LixUniversity of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0001-8685-3212
Sasha BernatskyMcGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0002-9515-2802
Suzanne N MorinMcGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0002-4317-492X
Michelle M GrahamUniversity of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0003-0708-7957
Aurore Fifi-MahUniversity of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0001-5417-9825
Shahin JamalUniversity of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-5870-3567
Janet RobertsDalhousie University, Halifax, Nova Scotia, Canada.ORCID https://orcid.org/0000-0002-3787-8541
Carrie YeUniversity of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0002-9858-5398

Funding

Carrie Ye was supported by a Canadian Institutes of Health Research Early Career Research Award PJF 198655the Canadian Institutes of Health Research PJT197771
6 · The paper itself

Abstract

objectiveImmune checkpoint inhibitors (ICIs) for cancer can lead to immune-related adverse events, including ICI-associated inflammatory arthritis (ICI-IA). There are no validated International Classification of Diseases (ICD) code-based case definitions for ICI-IA.

methodsWe conducted a validation study using the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) database. Rheumatologist-confirmed ICI-IA was the reference standard, defined as new onset of at least one swollen joint on examination or synovitis on imaging following ICI exposure, without another cause or pre-existing IA. We compared ICD-9 (714.x and 696.0) and ICD-10 (M05.x, M06.x, and M07.x) IA diagnostic codes against the reference standard. Seven core case definitions of different combinations of ICD codes from the Physician Claims Database (PCD) and the Discharge Abstract Database were tested. Results were stratified by sex. Sensitivity testing with additional criteria was also evaluated.

resultsWe included 228 patients in the final analysis: 100 with ICI-IA and 128 without ICI-IA. Sensitivity of the tested case definitions ranged from 1.0% to 88.0%, whereas specificity ranged from 86.7% to 100.0%. The case definition with at least one PCD IA code achieved the best balance of sensitivity (88.0%, 95% confidence interval [CI] 81.6%-94.4%) and specificity (86.7%, 95% CI 80.8%-92.6%). Case definition performances were similar between sexes. Additional criteria minimally improved specificity but sacrificed sensitivity.

conclusionICD code-based case definitions of ICI-IA can accurately detect ICI-IA and can be used to support ICI-IA surveillance and research with administrative health data.

Indexed as

ArthritisImmune Checkpoint InhibitorsInternational Classification of DiseasesNeoplasmsAgedCanadaDatabases, FactualFemaleHumansMaleMiddle AgedSensitivity and SpecificityImmune Checkpoint Inhibitors

Identifiers

PMID41869996
PMCPMC13619042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.